Efficacy of lanadelumab in patients with HAE is independent of body mass index: Findings from the HELP study

被引：0
|
作者：
Zanichelli, A. [1 ]
Hebert, J. [2 ]
Soteres, D. [3 ]
Hao, J. [4 ]
Lu, P. [4 ]
Busse, P. [5 ]
机构：
[1] Univ Milan, Dept Biomed & Clin Sci, ASST Fatebenefratelli Sacco, Luigi Sacco, Milan, Italy
[2] Ctr Rech Appl Allergie Quebec, Quebec City, PQ, Canada
[3] Asthma & Allergy Associates PC, Colorado Springs, CO USA
[4] Shire, Lexington, MA USA
[5] Icahn Sch Med Mt Sinai, Div Clin Immunol & Allergy, Dept Med, New York, NY 10029 USA
来源：
ALLERGY | 2018年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
1429
引用
收藏
页码：722 / 723
页数：2
相关论文
共 50 条
  • [1] Lanadelumab improves health-related quality of life in patients with hereditary Angioedema (HAE): findings from the HELP study
    Longhurst, Hilary
    Lumry, William
    Weller, Karsten
    Magerl, Markus
    Lu, Peng
    Jain, Gagan
    Lewis, Hannah
    Maurer, Marcus
    CLINICAL AND EXPERIMENTAL ALLERGY, 2018, 48 (11): : 1524 - 1525
  • [2] Pharmacokinetics and pharmacodynamics of lanadelumab in patients with HAE in the phase 3 HELP study
    Cicardi, M.
    Shennak, M.
    Zaragoza-Urdaz, R. H.
    Wang, Y.
    Lu, P.
    ALLERGY, 2018, 73 : 722 - 722
  • [3] Efficacy of lanadelumab is durable over time: Findings from the HELP Study and HELP OLE
    Kiani-Alikhan, S.
    Riedl, M.
    Bernstein, J. A.
    Anderson, J.
    Tachdjian, R.
    Lu, P.
    Ren, H.
    Aygoeren-Puersuen, E.
    ALLERGY, 2020, 75 : 59 - 59
  • [4] LANADELUMAB REDUCES HAE ATTACK RATE: INTERIM FINDINGS FROM THE HELP OPEN-LABEL EXTENSION STUDY
    Riedl, M.
    Bernstein, J.
    Yang, W.
    Longhurst, H.
    Magerl, M.
    Hebert, J.
    Shennak, M.
    Martinez-Saguer, I.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (05) : S37 - S37
  • [5] Lanadelumab reduces high morbidity attacks in patients with hereditary angioedema (HAE): results from the phase 3 HELP study
    Bernstein, J. A.
    Banerji, A.
    Schranz, J.
    Nurse, C.
    Riedl, M.
    Lu, P.
    ALLERGY, 2018, 73 : 288 - 289
  • [6] Lanadelumab And Cardiovascular Risk: Findings From The Phase 3 HELP Study
    Sexton, Daniel J.
    Brown, Nancy J.
    Lumry, William R.
    Gower, Richard G.
    Hao, James
    Lu, Peng
    Zafra, Heidi T. V.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB46 - AB46
  • [7] Efficacy and safety outcomes for switching to lanadelumab from prior LTP: Findings from an interim analysis of the HELP OLE study
    Magerl, M.
    Kiani-Alikhan, S.
    Riedl, M. A.
    Anderson, J. T.
    Nurse, C.
    Lu, P.
    ALLERGY, 2019, 74 : 755 - 755
  • [8] Effect of Lanadelumab on Coagulation Parameters in Patients With Hereditary Angioedema: Findings From The Phase 3 HELP Study
    Schmaier, Alvin H.
    Bauer, Kenneth A.
    Cicardi, Marco
    Hebert, Jacques
    Johnston, Douglas T.
    Busse, Paula J.
    Paes, Kim
    Sexton, Daniel J.
    Kenniston, Jon
    Nurse, Christina
    Zaragoza, Rafael H.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB42 - AB42
  • [9] LONG-TERM SAFETY OF LANADELUMAB IN HEREDITARY ANGIOEDEMA (HAE): INTERIM RESULTS FROM THE HELP OLE STUDY
    Johnston, D.
    Banerji, A.
    Nurse, C.
    Lu, P.
    Aygoren-Pursun, E.
    Kiani-Alikhan, S.
    Soteres, D.
    Lugar, P.
    Zuraw, B.
    Lockey, R.
    Schwartz, L.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S30 - S30
  • [10] Attack-Free Status of Patients With Hereditary Angioedema (HAE) During Extended Treatment With Lanadelumab in the HELP OLE Study
    Riedl, Marc
    Johnston, Douglas
    Lumry, William
    Bernstein, Jonathan
    Nurse, Christina
    Lu, Peng
    Maurer, Marcus
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB104 - AB104
12345